相关实验视频

Updated: Jul 19, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

克雷布斯··登·隆根-6作为纤维化间歇性肺部疾病的潜在预测生物标志物

Christoph Lederer¹, Katharina Mayer², Vivien Somogyi^2,3

¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik Heidelberg, University Hospital Heidelberg and German Center for Lung Research (DZL), Heidelberg, Germany, christoph.lederer@web.de.

Respiration; international review of thoracic diseases

|August 16, 2023

概括

在治疗纤维化间歇性肺病 (fILDs) 期间,Krebs von den Lungen-6 (KL-6) 水平显著下降. 降低KL-6与稳定的肺功能相关,表明其作为高加索患者预测生物标志物的潜力.

科学领域:

肺部病理学肺部病理学
生物标志物研究生物标志物研究
间歇性肺病间歇性肺病

背景情况:

纤维化间歇性肺病 (fILD) 的死亡率很高,因此在治疗期间需要有效的疾病监测.
克雷布斯··登·隆根-6 (KL-6) 被公认为fILD存在和严重性的生物标志物,特别是在亚洲人群中.

研究的目的:

调查KL-6作为fILDs预测生物标志物的实用性,特别是在高加索患者中.
评估正在接受治疗的fILD患者的KL-6水平与临床结果 (包括肺功能) 之间的相关性.

主要方法:

预计将招募47名患有FILD的白人患者.
在基线,6个月和12个月测量血清KL-6度.
临床特征和肺功能测试 (FVC,DLCOSB) 的评估,与KL-6水平和变化相关.

主要成果:

与健康对照组相比,fILD患者的基线KL-6水平明显高于健康对照组 (1,757 ± 1960 U/mL与265 ± 107 U/mL相比,p < 0.0001).
在治疗期间,KL-6水平显著下降 (p=0.032在6个月,p=0.041在12个月).
KL-6水平的变化与FVC (r = -0.562,p < 0.0001) 和DLCOSB (r = -0.405,p = 0.013) 的变化有负相关性. 稳定的FVC患者显示KL-6水平显著降低 (p = 0.022).

结论:

治疗期间KL-6水平的下降与fILD患者肺功能临床稳定相关.
KL-6显示出作为预测生物标志物的潜力,用于监测高加索种群的治疗反应.
需要进行更大规模的前性研究来证实这些发现,并确定KL-6在临床实践中的作用.

关键词:

间歇性肺病间歇性肺病克雷布斯··登·隆根 - - 6号预测性生物标志物预测性生物标志物

更多相关视频

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

相关概念视频

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Pulmonary Function Tests

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...